Literature DB >> 27158196

Dendritic cell-based cancer immunotherapy for colorectal cancer.

Mikio Kajihara1, Kazuki Takakura1, Tomoya Kanai1, Zensho Ito1, Keisuke Saito1, Shinichiro Takami1, Shigetaka Shimodaira1, Masato Okamoto1, Toshifumi Ohkusa1, Shigeo Koido1.   

Abstract

Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer-related mortality worldwide. Although systemic therapy is the standard care for patients with recurrent or metastatic CRC, the prognosis is extremely poor. The optimal sequence of therapy remains unknown. Therefore, alternative strategies, such as immunotherapy, are needed for patients with advanced CRC. This review summarizes evidence from dendritic cell-based cancer immunotherapy strategies that are currently in clinical trials. In addition, we discuss the possibility of antitumor immune responses through immunoinhibitory PD-1/PD-L1 pathway blockade in CRC patients.

Entities:  

Keywords:  Cancer immunotherapy; Colorectal cancer; Cytotoxic T lymphocyte; Dendritic cell; Immune-checkpoint inhibitors

Mesh：

Substances：

Year:  2016        PMID： 27158196      PMCID： PMC4853685          DOI： 10.3748/wjg.v22.i17.4275

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  91 in total

1.  Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.

Authors:  Ping Yu; Jason C Steel; Meili Zhang; John C Morris; Thomas A Waldmann
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects.

Authors:  Yoshihiro Oka; Haruo Sugiyama
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

3.  Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.

Authors:  P Brossart; G Stuhler; T Flad; S Stevanovic; H G Rammensee; L Kanz; W Brugger
Journal:  Cancer Res       Date:  1998-02-15       Impact factor: 12.701

4.  Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.

Authors:  W J Lesterhuis; I J M de Vries; D H Schuurhuis; A C I Boullart; J F M Jacobs; A J de Boer; N M Scharenborg; H M H Brouwer; M W M M van de Rakt; C G Figdor; T J Ruers; G J Adema; C J A Punt
Journal:  Ann Oncol       Date:  2006-04-06       Impact factor: 32.976

Review 5.  Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.

Authors:  Jasper J P van Beek; Florian Wimmers; Stanleyson V Hato; I Jolanda M de Vries; Annette E Sköld
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

Review 6.  Cell fusion: from hybridoma to dendritic cell-based vaccine.

Authors:  Jianlin Gong; Shigeo Koido; Stuart K Calderwood
Journal:  Expert Rev Vaccines       Date:  2008-09       Impact factor: 5.217

Review 7.  Cancer immunotherapy with mRNA-transfected dendritic cells.

Authors:  Eli Gilboa; Johannes Vieweg
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

8.  Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.

Authors:  Ayala Tamir; Ernesto Basagila; Arash Kagahzian; Long Jiao; Steen Jensen; Joanna Nicholls; Paul Tate; Gordon Stamp; Farzin Farzaneh; Phillip Harrison; Hans Stauss; Andrew J T George; Nagy Habib; Robert I Lechler; Giovanna Lombardi
Journal:  Cancer Immunol Immunother       Date:  2007-02-23       Impact factor: 6.968

9.  Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth.

Authors:  Y Oji; H Ogawa; H Tamaki; Y Oka; A Tsuboi; E H Kim; T Soma; T Tatekawa; M Kawakami; M Asada; T Kishimoto; H Sugiyama
Journal:  Jpn J Cancer Res       Date:  1999-02

10.  Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.

Authors:  Fares Al-Ejeh; Jocelyn M Darby; Michael P Brown
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240
View more
  19 in total

1.  Antigen-loaded dendritic cells triggers a specific cytotoxic T lymphocytes immune response against hepatocellular carcinoma: in vitro study.

Authors:  N E El-Ashmawy; E A El-Zamarany; E G Khedr; H A El-Bahrawy; O A El-Feky
Journal:  Clin Transl Oncol       Date:  2018-10-27       Impact factor: 3.405

Review 2.  Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines.

Authors:  Ali Azadi; Alireza Golchini; Sina Delazar; Fatemeh Abarghooi Kahaki; Seyed Mohsen Dehnavi; Zahra Payandeh; Shirin Eyvazi
Journal:  Biol Proced Online       Date:  2021-07-01       Impact factor: 3.244

Review 3.  Engineered in vitro tumor models for cell-based immunotherapy.

Authors:  Yuta Ando; Chelsea Mariano; Keyue Shen
Journal:  Acta Biomater       Date:  2021-04-20       Impact factor: 10.633

4.  A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment.

Authors:  Ko-Jiunn Liu; Tsu-Yi Chao; Jang-Yang Chang; Ann-Lii Cheng; Hui-Ju Ch'ang; Woei-Yau Kao; Yu-Chen Wu; Wei-Lan Yu; Tsai-Rong Chung; Jacqueline Whang-Peng
Journal:  J Biomed Sci       Date:  2016-08-24       Impact factor: 8.410

Review 5.  Strategy to targeting the immune resistance and novel therapy in colorectal cancer.

Authors:  Wang Gang; Jun-Jie Wang; Rui Guan; Sun Yan; Feng Shi; Jia-Yan Zhang; Zi-Meng Li; Jing Gao; Xing-Li Fu
Journal:  Cancer Med       Date:  2018-04-15       Impact factor: 4.452

Review 6.  Polyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer.

Authors:  Anna Maria Mileo; Paola Nisticò; Stefania Miccadei
Journal:  Front Immunol       Date:  2019-04-11       Impact factor: 7.561

Review 7.  Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis.

Authors:  Stephen J Gaudino; Pawan Kumar
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

Review 8.  Overcoming biological barriers to improve solid tumor immunotherapy.

Authors:  Anvay Ukidve; Katharina Cu; Ninad Kumbhojkar; Joerg Lahann; Samir Mitragotri
Journal:  Drug Deliv Transl Res       Date:  2021-02-20       Impact factor: 4.617

9.  Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer.

Authors:  Magdalena Szaryńska; Agata Olejniczak; Jarosław Kobiela; Dariusz Łaski; Zbigniew Śledziński; Zbigniew Kmieć
Journal:  Sci Rep       Date:  2018-08-13       Impact factor: 4.379

10.  A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

Authors:  Arjan A van de Loosdrecht; Sandra van Wetering; Saskia J A M Santegoets; Satwinder Kaur Singh; Corien M Eeltink; Yvonne den Hartog; Malika Koppes; Jorn Kaspers; Gert J Ossenkoppele; Ada M Kruisbeek; Tanja D de Gruijl
Journal:  Cancer Immunol Immunother       Date:  2018-07-23       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.